UBS Shrugs Abbott Laboratories' (ABT) Diagnostic Weakness Affirms ‘Buy’ Rating
Abbott Laboratories (NYSE:ABT) is one of the defensive stocks that billionaires are buying amid US trade tariff uncertainty.
Abbott Laboratories (ABT)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 11,862,823 | $1,613,462,695 | +2% | 0.64% |
| 2. | Diamond Hill Capital Ric Dillon | 5,912,808 | $804,201,016 | -3% | 3.7% |
| 3. | 2,120,700 | $288,436,407 | -3% | 0.05% | |
| 4. | AQR Capital Management Cliff Asness | 1,863,869 | $251,892,528 | +9% | 0.21% |
| 5. | Adage Capital Management Phill Gross And Robert Atchinson | 1,597,715 | $217,305,217 | +13% | 0.37% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $122.50 | 2,040 | $249,900.00 | 7,296 | 2021-02-23 | Filing | |
| $73.40 | 2,000 | $146,798.20 | 52,562 | 2019-04-22 | Filing | |
| $72.32 | 100 | $7,231.50 | 6,400 | 2019-01-31 | Filing | |
| $72.31 | 100 | $7,230.50 | 6,300 | 2019-01-31 | Filing | |
| $72.33 | 1,800 | $130,194.00 | 6,200 | 2019-01-31 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $134.55 | 5,550 | $746,758.05 | 51,003 | 2025-08-08 | Filing | |
| $129.66 | 2,600 | $337,116.00 | 34,058 | 2025-04-30 | Filing | |
| $136.65 | 200 | $27,329.00 | 71,928 | 2025-03-07 | Filing | |
| $133.82 | 91,167 | $12,199,967.94 | 71,928 | 2025-03-06 | Filing | |
| $138.17 | 949 | $131,123.33 | 74,381 | 2025-03-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 172,800,851 | $23,502,643,745 | 0.38% | |
| 2. | 141,287,026 | $19,216,448,383 | 0.37% | |
| 3. | 78,354,270 | $10,656,964,263 | 0.4% | |
| 4. | 60,136,663 | $8,177,837,038 | 1.41% | |
| 5. | 41,766,185 | $5,680,578,507 | 1.14% |
News See All
11 Defensive Stocks Billionaires are Buying amid US Trade Tariff Uncertainty
Usually, anxiety triggered by geopolitical tensions, monetary policy uncertainties, trade wars, and tariffs would be enough to prompt investors to adopt defensive strategies in the markets.
Leerink Partners Decreases PT on Abbott Laboratories (ABT) to $136 From $143, Maintains a Hold Rating
Abbott Laboratories (NYSE:ABT) is one of the top low volatility healthcare stocks to buy now.
RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)
Abbott Laboratories (NYSE:ABT) ranks among the best low volatility stocks to buy according to analysts.
Oversold Abbott Laboratories (ABT) Could Offer a Healthy Dividend Opportunity
The company reported strong earnings in the second quarter of 2025. It posted revenue of $11.1 billion, which showed a 7.37% growth on a YoY basis.
10 Oversold Dividend Stocks To Buy According to Hedge Funds
Since its April low, the S&P 500 Index has climbed nearly 13%, reaching record highs— a positive signal for long-term market trends.
Top 15 Low Volatility Healthcare Stocks to Buy Now
A majority of Americans have experienced the frustration of getting a healthcare insurance denial, often times finding no solution despite emails with service providers and phone calls with carriers.
Abbott Laboratories (ABT): A Bull Case Theory
We came across a bullish thesis on Abbott Laboratories on r/ValueInvesting subreddit by anonymous_sheep1. In this article, we will summarize the bulls’ thesis on ABT.
20 Best Low Volatility Stocks to Buy According to Analysts
Consumers remain cautious about potential price hikes, but their biggest concerns about tariff-induced inflation have subsided, according to a University of Michigan survey published on July 18.
Abbott Laboratories (ABT): I Am Very Upset With Abbott," Says Jim Cramer
Abbott Laboratories (NYSE:ABT) is a healthcare company. While it was one of Cramer’s top stocks for most of this year, this show saw the CNBC TV host take a different tone.
Billionaire Hedge Funds
